一项关于三氧化矿物凝聚体用于乳牙牙髓切断术的随机试验。

A randomized trial of mineral trioxide aggregate cements in primary tooth pulpotomies.

作者信息

Celik Berna, Ataç Atila S, Cehreli Zafer C, Uysal Serdar

机构信息

Department of Pediatric Dentistry, School of Dentistry, Hacettepe University, Ankara, Turkey.

Department of Pediatric Dentistry, in the school of Dentistry, Hacettepe University, Ankara, Turkey.

出版信息

J Dent Child (Chic). 2013 Sep-Dec;80(3):126-32.

PMID:24351693

Abstract

PURPOSE

The purpose of this study was to compare the outcome of primary tooth pulpotomies using two different white mineral trioxide aggregate (MTA) cements and calcium hydroxide (CH).

METHODS

Primary molars (N=139) from three- to nine-year-old children were randomly assigned to be treated using either ProRoot MTA (N=46), MTA Angelus (N=45), or CH paste (N=48) as pulpotomy medicaments. All pulpotomized teeth received a Class I amalgam as a final restoration. Recall examinations were carried out at one, three, six, 12, 18, and 24 months.

RESULTS

The 24-month cumulative clinical success rates for ProRoot MTA, MTA Angelus, and CH were approximately 98 percent, 96 percent, and 77 percent, respectively. The cumulative radiographic success rates for ProRoot MTA, MTA Angelus, and CH were approximately 98 percent, 91 percent, and 45 percent, respectively. For all parameters evaluated, the MTA cements showed similar clinical and radiographic outcomes (P>.05), which were significantly better than those of CH (P<.05). The two-year clinical and radiographic survival probabilities for ProRoot MTA and MTA Angelus were comparable (P=.62 and P=.20, respectively) and superior to calcium hydroxide (all P>.05).

CONCLUSIONS

ProRoot MTA and MTA Angelus showed similar and favorable success rates as pulpotomy materials in primary molars.

摘要

目的

本研究的目的是比较使用两种不同的白色矿物三氧化物凝聚体（MTA）水门汀和氢氧化钙（CH）进行乳牙牙髓切断术的效果。

方法

将3至9岁儿童的乳牙（N = 139颗）随机分配，分别使用ProRoot MTA（N = 46颗）、MTA Angelus（N = 45颗）或CH糊剂（N = 48颗）作为牙髓切断术药物进行治疗。所有接受牙髓切断术的牙齿均采用I类银汞合金进行最终修复。在1、3、6、12、18和24个月时进行复查。

结果

ProRoot MTA、MTA Angelus和CH的24个月累积临床成功率分别约为98%、96%和77%。ProRoot MTA、MTA Angelus和CH的累积影像学成功率分别约为98%、91%和45%。对于所有评估参数，MTA水门汀显示出相似的临床和影像学结果（P>0.05），显著优于CH（P<0.05）。ProRoot MTA和MTA Angelus的两年临床和影像学生存概率相当（分别为P = 0.62和P = 0.20），且优于氢氧化钙（所有P>0.05）。